Disc Medicine(IRON) - 2024 Q4 - Annual Results

Financial Performance - Disc Medicine reported a net loss of $109.4 million for the full year 2024, compared to a net loss of$76.4 million in 2023, reflecting an increase of 43%[13] - Total operating expenses for 2024 were $129.7 million, compared to$91.1 million in 2023, marking a 42% increase[17] - Total stockholders' equity increased to $443.6 million as of December 31, 2024, compared to$345.1 million in 2023[19] Research and Development - Research and development expenses increased to $96.7 million in 2024 from$69.3 million in 2023, driven by advancements in clinical studies and increased headcount[13] - Positive data from the Phase 1b trial of DISC-0974 in myelofibrosis anemia was presented, with initial data from the ongoing Phase 2 expected in H2 2025[4] - The company presented positive preclinical data for DISC-3405 in sickle cell disease, highlighting its potential therapeutic benefits[4] Cash Position and Funding - The company ended 2024 with $490 million in cash, cash equivalents, and marketable securities, up from$360.4 million at the end of 2023, providing a cash runway into 2028[4] - The company completed a public offering in January 2025, raising approximately $259 million, which will support ongoing operations[4] Future Plans - The company plans to submit a New Drug Application (NDA) for bitopertin in the second half of 2025, targeting accelerated approval based on clinical data[4] - The company is on track to initiate the APOLLO trial for bitopertin by mid-2025, following alignment with the FDA on trial design[4]